Harbor Investment Advisory’s Amicus Therapeutics FOLD Stock Holding History

Harbor Investment Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,324	Closed	-$66.9K	–	1242
2023 Q2	$66.9K	Hold	5,324	–	–	0.01%	620
2023 Q1	$59K	Hold	5,324	–	–	0.01%	660
2022 Q4	$65K	Hold	5,324	–	–	0.01%	612
2022 Q3	$56K	Hold	5,324	–	–	0.01%	655
2022 Q2	$57K	Hold	5,324	–	–	0.01%	669
2022 Q1	$50K	Hold	5,324	–	–	0.01%	746
2021 Q4	$61K	Hold	5,324	–	–	0.01%	680
2021 Q3	$51K	Hold	5,324	–	–	0.01%	735
2021 Q2	$51K	Buy	5,324 +654	+14%	+$6.38K	0.01%	701
2021 Q1	$46K	Buy	4,670 +2,026	+77%	+$31.4K	0.01%	699
2020 Q4	$61K	Buy	2,644 +2,231	+540%	+$45.6K	0.01%	581
2020 Q3	$6K	Buy	+413	New	+$6.02K	﹤0.01%	919

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Harbor Investment Advisory's FOLD Position: Q3 2023 in Review

Harbor Investment Advisory sold out of Amicus Therapeutics (FOLD) in Q3 2023, closing a stake of 5,324 shares — an estimated $66.9K sold.

Harbor Investment Advisory first reported a position in FOLD in Q3 2020 and held it in 12 quarters. The position peaked at $66.9K in Q2 2023. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

Harbor Investment Advisory reported no remaining Amicus Therapeutics position as of Q3 2023 after selling out during the quarter.
Harbor Investment Advisory sold 5,324 Amicus Therapeutics shares in Q3 2023, an estimated $66.9K.
Harbor Investment Advisory first reported a position in Amicus Therapeutics in Q3 2020 and held it in 12 quarters.
Harbor Investment Advisory's Amicus Therapeutics position peaked at $66.9K in Q2 2023.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on Harbor Investment Advisory's 13F filing for Q3 2023, filed 13 Oct 2023.